The economics of parallel trade

Area of Science:

• Health Economics
• Pharmaceutical Policy
• European Union Studies

Background:

• The European Union (EU) has seen increased pharmaceutical parallel trade due to new member states and harmonized regulations.
• Parallel trade creates tension between national pricing autonomy, free trade principles, and the need to fund innovative research and development (R&D).

Purpose of the Study:

• To analyze the economic impact of pharmaceutical parallel trade within the EU.
• To evaluate how parallel trade affects pharmaceutical pricing, R&D investment, and consumer welfare.
• To explore policy options for preserving price differentials and ensuring continued drug development.

Main Methods:

• Economic analysis of trade principles and pricing strategies.
• Examination of the relationship between pharmaceutical prices, R&D costs, and market demand elasticity.
• Review of regulatory impacts and policy implications.

Main Results:

• Parallel trade in pharmaceuticals does not generate typical efficiency gains; it reduces economic welfare by eroding price differences between markets.
• Aggressive regulation, not superior efficiency, drives low prices in some countries, undermining global R&D cost recovery.
• Uniform 'euro' pricing, a response to parallel trade, risks higher prices or reduced access for consumers in low-income countries and potentially fewer new drugs overall.

Conclusions:

• Pharmaceutical parallel trade, while seemingly promoting free trade, can harm economic welfare and drug innovation by forcing price convergence.
• Policy interventions, such as exempting on-patent drugs or using confidential contracting for discounts, are needed to maintain price differentials.
• Preserving price differentials is vital for sustaining the global R&D model and ensuring future drug development and access.